Format

Send to

Choose Destination
Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, New York.
2
Beth Israel Deaconess Medical Center, Boston, Massachusetts.
3
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.
4
Moffit Cancer Center, Tampa, Florida.
5
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
6
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
7
Highlands Oncology Group, Fayetteville, Arkansas.
8
Penn State Cancer Institute, Hershey, Pennsylvania.
9
Nebraska Methodist Hospital, Omaha, Nebraska.
10
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
11
Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina.
12
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
13
New York Oncology Hematology, Albany, New York.
14
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
15
Rocky Mountain Cancer Centers, Aurora, Colorado.
16
Acceleron Pharma Inc, Cambridge, Massachusetts.
17
Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Abstract

BACKGROUND:

In a prior open-label study, the combination of dalantercept, a novel antiangiogenic targeting activin receptor-like kinase 1 (ALK1), plus axitinib was deemed safe and tolerable with a promising efficacy signal in patients with advanced renal cell carcinoma (RCC).

METHODS:

In the current phase 2, randomized, double-blind, placebo-controlled study, patients with clear cell RCC previously treated with 1 prior angiogenesis inhibitor were randomized 1:1 to receive axitinib plus dalantercept versus axitinib plus placebo. Randomization was stratified by the type of prior therapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were PFS in patients with ≥2 prior lines of anticancer therapy, overall survival, and the objective response rate.

RESULTS:

Between June 10, 2014, and February 23, 2017, a total of 124 patients were randomly assigned to receive axitinib plus dalantercept (59 patients) or placebo (65 patients). The median PFS was not found to be significantly different between the treatment groups (median, 6.8 months vs 5.6 months; hazard ratio, 1.11 [95% CI, 0.71-1.73; P = .670]). Neither group reached the median overall survival (hazard ratio, 1.39 [95% CI, 0.70-2.77; P = .349]). The objective response rate was 19.0% (11 of 58 patients; 95% CI, 9.9%-31.4%) in the dalantercept plus axitinib group and 24.6% (15 of 61 patients; 95% CI, 14.5%-37.3%) in the placebo plus axitinib group. At least 1 treatment-emergent adverse event of ≥grade 3 was observed in 59% of patients (34 of 58 patients) in the dalantercept group and 64% of patients (39 of 61 patients) in the placebo group. One treatment-related death occurred in the placebo plus axitinib group.

CONCLUSIONS:

Although well tolerated, the addition of dalantercept to axitinib did not appear to improve treatment-related outcomes in previously treated patients with advanced RCC.

KEYWORDS:

angiogenesis; antiangiogenic agents; chemotherapy; drug therapy; randomized controlled trial; renal cell carcinoma

PMID:
30951193
PMCID:
PMC6602847
[Available on 2020-07-15]
DOI:
10.1002/cncr.32061

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center